The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 38.70
Bid: 38.50
Ask: 39.50
Change: -0.30 (-0.77%)
Spread: 1.00 (2.597%)
Open: 39.00
High: 38.70
Low: 38.70
Prev. Close: 39.00
VLG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Share Placing

28 Nov 2014 07:00

RNS Number : 2513Y
Venture Life Group PLC
28 November 2014
 



Venture Life Group plc

("Venture Life" or "the Company" or "the Group")

 Share Placing

 

Bracknell, UK - 28 November 2014: Venture Life Group plc (AIM: VLG), the international consumer products group addressing the self-care needs of the ageing population, announces that it has raised £4,230,000 (gross) through a subscription by existing institutional shareholders for 4,500,000 new ordinary shares of 0.3 pence per share ("Subscription Shares") at a price of 94 pence per share representing a discount of 0.5 per cent. to the closing mid-market price on 27 November 2014 (the "Subscription").

 

The Company intends to use the net proceeds of the Subscription to invest further in Business Development resource and New Product Development, as well as in the Group's manufacturing facility in Italy.

 

The Subscription Shares will, when issued, rank pari passu in all respects with the existing ordinary shares of 0.3p each in Venture Life ("Ordinary Shares"). Application has been made to the London Stock Exchange for admission to trading on AIM of the Subscription Shares ("Admission"). Completion of the Subscription is conditional on, inter alia, Admission.

 

It is expected that Admission will become effective and that dealings in the Subscription Shares will commence at 8.00 a.m. on or around 3 December 2014.

 

Following the issue and allotment of the Subscription Shares, the Company's enlarged issued ordinary share capital will comprise 34,403,534 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. This figure of 34,403,534 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

 

- Ends -

 

For further information please contact:

Venture Life Group PLC

Jerry Randall, Chief Executive Officer

James Hunter, Chief Financial Officer +44 (0) 1344 742 870

 

Panmure Gordon (UK) Limited Freddy Crossley / Duncan Monteith +44 (0) 20 7886 2500Corporate Finance

Tom SalvesenCorporate Broking

 

Square1 Consulting

David Bick +44 (0) 20 7929 5599

Mark Longson

About Venture Life

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product range and pipeline currently include food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin. The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

 

Through its topical development and manufacturing business, Biokosmes, the Group also provides development and manufacturing services to companies in the medical device and cosmetic sectors.

The Group's own branded products are currently sold or partnered in over 50 countries and currently include:

· food supplements to maintain brain function and memory;

· dermo-cosmetics for addressing the signs of skin ageing and hair loss, and

· medical devices for improving conditions such as minor aches and pains, dry eyes and itchy skin.

 

The Company has a healthy development pipeline including products in areas such as diabetes, cardiovascular health, obesity, cognitive function and skin ageing. Products coming from the pipeline will be expected to have intellectual property protection and be supported by independent clinical evidence of efficacy.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEUBORRSBAAUUA
Date   Source Headline
8th Dec 202012:00 pmRNSResult of General Meeting and Open Offer
24th Nov 20207:00 amRNSPDMR Dealings and Issue of Equity
23rd Nov 20208:52 amRNSHolding(s) in Company
20th Nov 20201:00 pmRNSPlacing, Open Offer and Notice of General Meeting
16th Nov 20209:05 amRNSSecond Price Monitoring Extn
16th Nov 20209:00 amRNSPrice Monitoring Extension
16th Nov 20207:00 amRNSResults of in-vitro clinical trial published
9th Nov 20204:40 pmRNSSecond Price Monitoring Extn
9th Nov 20204:36 pmRNSPrice Monitoring Extension
3rd Nov 20209:33 amRNS1000 Companies to Inspire Britain 2020 Report
19th Oct 202012:24 pmRNSHolding(s) in Company
15th Oct 20202:57 pmRNSExercise of Share Options & Voting Rights
9th Oct 20201:39 pmRNSHolding(s) in Company
5th Oct 20201:21 pmRNSHolding(s) in Company
24th Sep 20207:00 amRNSHalf-year Report
25th Aug 202011:59 amRNSHolding(s) in Company
24th Aug 20207:00 amRNSKey oral care brand - clinical trial on COVID-19
20th Jul 20209:05 amRNSSecond Price Monitoring Extn
20th Jul 20209:00 amRNSPrice Monitoring Extension
20th Jul 20207:00 amRNSHalf Year Trading Update
13th Jul 20207:00 amRNSAppointment of Joint Broker
22nd Jun 20204:41 pmRNSSecond Price Monitoring Extn
22nd Jun 20204:36 pmRNSPrice Monitoring Extension
22nd Jun 202011:05 amRNSSecond Price Monitoring Extn
22nd Jun 202011:00 amRNSPrice Monitoring Extension
11th Jun 20207:00 amRNSHolding(s) in Company
9th Jun 20207:00 amRNSTrading update
3rd Jun 202010:52 amRNSResult of AGM
3rd Jun 20207:00 amRNSAGM Statement
29th May 20203:56 pmRNSHolding(s) in Company
20th May 20207:59 amRNSHolding(s) in Company
19th May 20203:26 pmRNSHolding(s) in Company
19th May 20203:25 pmRNSHolding(s) in Company
19th May 20201:29 pmRNSDirector/PDMR Shareholding
15th May 20207:00 amRNSComment on mouthwash & COVID-19 transmission
29th Apr 20204:15 pmRNSHolding(s) in Company
27th Apr 20209:06 amRNSSecond Price Monitoring Extn
27th Apr 20209:00 amRNSPrice Monitoring Extension
27th Apr 20207:00 amRNSExclusive Long Term Agreement Secured in China
16th Apr 20203:13 pmRNSHolding(s) in Company
9th Apr 20207:00 amRNSFinal Results
1st Apr 20203:10 pmRNSNotice of Results
25th Mar 20207:00 amRNSNotice of Results Update and Trading Update
9th Mar 20207:00 amRNSTrading Update and Notice of Results
21st Feb 20207:00 amRNSDirector/PDMR Shareholding
24th Jan 202012:37 pmRNSCompletion of Acquisition
9th Jan 20204:28 pmRNSDirector/PDMR Shareholding
6th Jan 20203:38 pmRNSGrant of Options
19th Dec 20197:00 amRNSAcquisition and Trading Update
18th Nov 20192:02 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.